GeneDx Holdings Corp. $WGS Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC decreased its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 25.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 266,636 shares of the company’s stock after selling 90,666 shares during the period. Fred Alger Management LLC’s holdings in GeneDx were worth $34,679,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Goldman Sachs Group Inc. lifted its holdings in shares of GeneDx by 4.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock valued at $158,738,000 after acquiring an additional 52,322 shares in the last quarter. Vanguard Group Inc. lifted its holdings in GeneDx by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after buying an additional 18,647 shares in the last quarter. Franklin Resources Inc. lifted its holdings in GeneDx by 60.4% in the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after buying an additional 411,607 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after buying an additional 474,167 shares in the last quarter. Finally, ARK Investment Management LLC lifted its holdings in GeneDx by 35.3% in the 4th quarter. ARK Investment Management LLC now owns 604,561 shares of the company’s stock worth $78,629,000 after buying an additional 157,582 shares in the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Price Performance

WGS opened at $60.60 on Wednesday. The company has a 50-day moving average of $54.74 and a 200-day moving average of $88.21. The company has a market capitalization of $1.80 billion, a P/E ratio of -22.61 and a beta of 1.96. GeneDx Holdings Corp. has a 1-year low of $32.21 and a 1-year high of $170.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the previous year, the firm posted ($0.23) EPS. Equities analysts expect that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Insider Activity at GeneDx

In related news, Director Casdin Capital, Llc bought 50,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was bought at an average price of $52.86 per share, with a total value of $2,643,000.00. Following the transaction, the director owned 3,707,164 shares of the company’s stock, valued at approximately $195,960,689.04. This trade represents a 1.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Keith A. Meister bought 46,273 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $38.91 per share, with a total value of $1,800,482.43. Following the transaction, the director directly owned 4,784,570 shares in the company, valued at approximately $186,167,618.70. The trade was a 0.98% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders purchased 2,256,420 shares of company stock worth $93,144,340 and sold 54,402 shares worth $3,395,647. Insiders own 25.17% of the company’s stock.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: Multiple law firms issued fresh reminders that a securities class action has been filed against GeneDx, with lead-plaintiff deadlines approaching for investors who bought shares between April 16, 2025 and May 4, 2026. The lawsuits center on claims that the company misrepresented acquisition performance and other business risks. Article Title
• Negative Sentiment: The legal scrutiny is tied to GeneDx’s disastrous first-quarter 2026 report, which previously triggered a sharp stock drop and included a large write-off related to the Fabric Genomics acquisition, reinforcing investor concerns about execution and deal quality. Article Title
• Neutral Sentiment: GeneDx also named Mark Gardner president to help lead its next phase of scale and growth, a management move that could support longer-term execution but is not currently offsetting the lawsuit-related overhang. Article Title

Wall Street Analyst Weigh In

A number of equities analysts have commented on WGS shares. Wells Fargo & Company reiterated an “overweight” rating and issued a $75.00 price objective (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Guggenheim cut their price objective on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Craig Hallum reiterated a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a report on Tuesday, May 5th. Piper Sandler reiterated an “overweight” rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Finally, Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a report on Monday, February 23rd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus price target of $96.43.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.